Perhaps the more interesting development (more so than the rather waifish additional dollars spent) in these later-filed fourth quarter 2013 Senate Form LD-2 reports is the new/not previously disclosed items in the list of matters on which Merck deployed the lobbyists. Take a look:
. . . .[Mehlman Vogel Castaganetti:]
▲ Budget issues, including Medicare Part D rebates and reductions in Medicare Part D low income subsidies.
▲ Discussions and possible legislation amending Title XVIII, Part D (Medicare Part D) of SSA. . . .
▲ Amendments including issues of "non-interference clause" and Medicare Advantage.
▲ Independent Payment Advisory Board.
▲ Medicare and Entitlement Reform.
▲ Low income subsidy co-pays.
▲ H.R. 1407, Annual Drug User Fee Agreements of 2013.
▲ Trade promotion authority; trade with India. . . .
[Forbes-Tate:]
▲ Issues relating to trade negotiations; PNTR with Russia.
▲ Issues related to pharmaceutical drug safety track and trace program legislation.
▲ Issues related to comparative effectiveness, issues related to the Independent Payment Advisory Board. . . .
As ever, we will keep you up to date.
No comments:
Post a Comment